Compare Salesforce Inc (CRM) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Davita Inc — how do they compare? Salesforce Inc trades at $228.79 (market cap $184.81B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Salesforce Inc is far larger — about 16.4× Davita Inc's market cap, and Salesforce Inc pays a 0.78% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Davita Inc for 113 Days on average.
| CRM | DVA | |
|---|---|---|
Market Cap | $184.81B | $11.28B |
Volume | 5,173,995 | 650,294 |
Sector | Technology | Health |
52-Week High | $266.23 | $240.96 |
52-Week Low | $150.12 | $103.87 |
Typical Hold Time | 89 Days | 113 Days |
Enterprise Value | $215.15B | $24.00B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected), robust profitability (77.28% gross margin, 21.99% net margin), and healthy cash flow generation ($13.09B operating cash flow in 2025). Technical indicators remain bearish with current price near pivot point support at $224.
Outlook remains positive long-term given Salesforce's dominant market position, AI monetization growth (Agentforce ARR up 107% quarterly), and analyst consensus target of $271.91 (21% upside). Near-term risks include software sector volatility and competitive AI threats, but strong fundamentals support recovery potential from current discounted valuation levels.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
